SentryX and the EIC Accelerator: Opioid-Free Spine Surgery Relief

SentryX, a Dutch company whose CORDIS address is in Austerlitz near Utrecht, has developed BR-003, a ring-shaped, biodegradable gelatin hydrogel that surgeons slide onto pedicle screws during spine fixation surgery, where it releases the local anaesthetic bupivacaine for more than 72 hours. The aim is to replace the high-dose opioids that patients receive after one of the most painful operations. SentryX was selected in the EIC Accelerator's January 2023 cut-off and announced €15.5 million in EIC funding; its final report describes this as "a €2.5 million grant and €13 million equity". The grant project, OPERAS, cost €5.69 million and ran from April 2023 to March 2026, according to CORDIS.

The project is closed. Its final report states that a Phase Ib trial with 11 patients in the Netherlands and Switzerland met its primary safety endpoint in every patient, with mean peak blood bupivacaine of 149 ng/mL against a 2,000 ng/mL threshold, and that no product-related serious adverse events occurred up to a year after surgery, according to the CORDIS reporting page. The safety results were published in a peer-reviewed journal, EMA scientific advice on a single adaptive Phase II/III pivotal trial was obtained in February 2026, and "all 14 deliverables and all 3 milestones of the project were achieved".

Where SentryX Stands Now

SentryX is preparing its pivotal trial and in February 2026 reported a key step for its scaled-up production line, according to its news page. It formed a supervisory board in May 2025, added four spine surgeons to an advisory board in November 2025, and won the ATiO Emerging Company Contest in June 2026. The company states that BR-003 "has not been approved by the FDA, EMA, or any other regulatory authority". No start date or financing for the pivotal trial has been announced.

The Technology: A Ring of Slow-Release Anaesthetic

The SentryX ring keeps releasing anaesthetic for more than 72 hours, nine times longer than conventional injections, the company says, and then dissolves. It is made from an ultra-pure modified gelatin developed in-house and fits commercial pedicle screws without changing the operation. In the trial, bupivacaine stayed measurable in blood for two weeks.

What the EIC Award Promised, and What the Record Shows

The project had three goals: a Phase Ib first-in-human safety trial, a market access strategy, and regulatory preparation. All three were completed, and the safety data was published. The efficacy findings, 42% less opioid use and 49% lower back pain than 41 standard-care patients, are exploratory: they come from a small trial compared with an observational group, not a randomised control arm.

1. Phase Ib safety trialDeliveredEndpoint met in all 11.
2. Peer-reviewed publicationDeliveredBMJ Group journal.
3. Regulatory preparationDeliveredEMA advice, 2026.
4. Proven efficacyNot yetPivotal trial needed.

The Money

According to the final report the EIC committed €13 million of equity alongside the grant. How much of that has been invested, and what other investors hold, is not public, and SentryX's accounts could not be checked from free sources. The company has not disclosed how it will fund the Phase II/III trial.

What Cannot Be Checked

Why Europe Should Care

The final report cites an 18% risk of opioid dependence after spine surgery and about 1.2 million spine fixation procedures a year in Europe and the US. A safe, non-opioid way to control that pain would matter to patients and health systems. SentryX has shown the approach is safe in a small trial; whether it works still has to be proved.

The Verdict

SentryX and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.